Plain-English translation of NCT06979336 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help people with moderate to severe ulcerative colitis—especially those whose disease hasn't improved with current treatments. The trial will compare this medication against a placebo (a fake pill) for the first 12 weeks, and then all participants will receive the active medication for an additional 40 weeks. Researchers will measure how well the treatment works, how safe it is, and how your body processes it.
Many people with ulcerative colitis don't respond well enough to existing medications, or they stop working over time. This trial is exploring whether this new treatment can offer hope to those patients who need better options.
You likely qualify if…
You likely don't qualify if…
You will have a screening period of up to 5 weeks to confirm you qualify. Then you'll enter the 12-week main treatment phase, where you'll randomly receive either the new medication or a placebo. After that, everyone—including those who received placebo—will receive the active medication for 40 additional weeks. Throughout the trial, you'll have regular clinic visits to check how you're doing, provide blood samples, and have your symptoms assessed. A final safety follow-up will occur after your last dose.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
United States